Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The World Health Organization classifies atypical chronic myeloid leukemia (aCML) as a myeloproliferative/myelodisplastic hematological disorder. The primary manifestations are leukocytosis with disgranulopoiesis, absence of basophilia and/or monocytosis, splenomegaly and absence of Philadelphia chromosome or BCR/ABL fusion. Overall 50-65% of patients demonstrate karyotypic abnormalities, although no specific cytogenetic alterations have been associated with this disease. X chromosome alterations have been rarely reported in myeloid malignancies. Although Isodicentric X, idic(X)(q13) is well known in females with myelodysplastic syndromes (MDS), little data are available on X isochromosome and its pathogenetic potential in these disorders. i(X)(p10) is observed in a variety of hematologic malignancies, both myeloid and lymphoid, as a unique abnormality, as well as part of a more complex karyotype, in females and less frequently in male patients. The present report describes the first patient with aCML, with documented isolated i(X)(p10), who developed a secondary acute myeloid leukemia (sAML).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791424PMC
http://dx.doi.org/10.3892/mco.2017.1543DOI Listing

Publication Analysis

Top Keywords

myeloid leukemia
16
atypical chronic
8
chronic myeloid
8
acute myeloid
8
myeloid
6
identification ixp10
4
ixp10 sole
4
sole molecular
4
molecular abnormality
4
abnormality atypical
4

Similar Publications

Complex chromosomal changes in Acute Myeloid Leukemia (AML) are highly heterogeneous, with disease progression shaped by both the number and nature of abnormalities. Rarely do, multiple unrelated clones with independent chromosomal changes coexist at diagnosis. Present study showcases a comprehensive characterization of two cytogenetically distinct complex clones in AML, driven by non-cyclic and chromoplexy mechanisms, highlighting their co-existence with key molecular alterations (TP53, NF1, DNMT3A, TET2) along with their potential contribution to clonal evolution.

View Article and Find Full Text PDF

Germline DDX41 mutations (DDX41mut) are identified in approximately 5% of myeloid malignancies with excess of blasts, representing a distinct MDS/AML entity. The disease is associated with better outcomes compared to DDX41 wild-type (DDX41WT), but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Due to the recent identification of DDX41mut, data on post-HSCT outcomes remain limited.

View Article and Find Full Text PDF

Background: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.

Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.

View Article and Find Full Text PDF

Background: This study aimed to identify the diagnostic and prognostic ability of serum miR-411-3p in patients with acute myeloid leukemia (AML).

Methods: Blood samples were collected from 60 AML patients and 60 healthy controls to measure serum miR-411-3p and thereafter discuss its potential clinical value.

Results: Serum miR-411-3p was decreased in AML patients and was even lower in those with M4/M5 subtypes or high white blood cell count or adverse cytogenetic risk.

View Article and Find Full Text PDF

Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of peripheral T-cell lymphoma, accounting for 1 - 2% of non-Hodgkin lymphomas. Diagnosis is challenging, and there is no established standard first-line treatment. This case report highlights a rare progression from AITL to therapy-related acute myeloid leukemia (AML-pCT) following cytotoxic chemotherapy.

View Article and Find Full Text PDF